Impact of Rheumatoid Arthritis on Memory: An Observational Case-control study

Faiq I. Gorial¹, Ali Ameer Hamzah²
¹Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
²Rheumatology Unit, Baghdad Teaching Hospital, Baghdad, Iraq

Article History:
Received on: 04.12.2019
Revised on: 06.01.2020
Accepted on: 10.01.2020

Keywords:
Rheumatoid arthritis, Cognition, Cognitive impairment test, Cognitive dysfunction

ABSTRACT
Rheumatoid arthritis (RA) is the most common chronic inflammatory polyarthritis with a significant impact on the quality of life. It is usually not associated with the central nervous system and brain changes. Neuropsychological impairment is not commonly associated with RA. However, recent studies have indicated that a link may exist between RA and cognitive impairment, but the prevalence rate was uncertain. This study aimed to evaluate the impact of rheumatoid arthritis (RA) on memory. This case-control study included 130 consecutive RA patients compared with 130 healthy controls matched in age and sex. Demographic and clinical characteristics were recorded. Six-item Cognitive Impairment Test (6CIT) - Kingshill Version 2000 was used to assess the memory. RA patients had more memory impairment than controls [47(69.1%) versus 21(30.9%) [OR (95% CI) = 2.939(1.632-5.294), p<0.001]. Age and prednisolone use were significantly and positively correlated with cognitive impairment (partial correlation (r = 0.346, p<0.001; r=0.224, p=0.012 respectively) while educational level was significantly and negatively correlated with CIT (r=-0.489, p<0.001). In conclusion, RA patients had a high risk of cognitive impairment. Increased age, being employed, use of oral glucocorticoids, low education. And low family income was a significant predictor of cognitive impairment. This suggest early diagnosis and treatment of RA may prevent cognitive impairment.

INTRODUCTION
Rheumatoid arthritis has a significant permanent functional impairment and disability (Erickson et al., 2017; Shah et al., 2017). Typically, the neuropsychological disorder does not require RA. Recent studies have shown that there may be a correlation between RA and cognitive impairment and that even mild cognitive impairment can interfere with daily working conditions for people with RA (Julian et al., 2012). While certain studies found a link between RA and cognitive impairment (Gorelick, 2010), others found no such correlation (Boyd et al., 2010). A large retrospective population-based study found that those who have a history of RA were considerably more likely to have experienced cognitive impairment over a 21-year period than those with other joint diseases (Wallin et al., 2012). Several mechanisms for RA memory impairment have been proposed, including a chronic systemic inflammatory process involving all organs. Neural tissue (Kurne et al., 2010) and...
Nevertheless, side effects associated with chronic systemic inflammation and autoantibodies can be accelerated (Pamuk et al., 2013) as well as the effects associated with neural tissue, in particular, glucocorticoid (Coluccia et al., 2008) and methotrexate (Pamuk et al., 2013). Intact cognitive function in persons with chronic conditions, like RA, is essential to perform certain basic functions. Cognitive affected patients have increased behavioral issues, decreased adherence to medications and reduced quality of life (Appenzeller et al., 2004; Shin et al., 2012). This study was designed to investigate memory impairment in RA and to assess possible predictors.

**PATIENTS AND METHODS**

**Study design**

This is a case-control study done in Medical City Hospital from October 2017 till June 2018. Ethical approval was taken from the Medical Department, College of Medicine, University of Baghdad. Participant's consent was taken for inclusion in the study.

**Participants**

**Patients group**

**Inclusion criteria**

1. Patients with RA and their age >16 years (Aletaha et al., 2010).

**Exclusion criteria**

1. Overlapping other inflammatory arthritis like systemic lupus erythematosus, systemic sclerosis, ankylosing spondylitis
2. Infection
3. Tumors
4. Kidney and liver diseases
5. Neuropsychiatric problems
6. Medications known to affect cognitive function

**Control group**

**Inclusion criteria, healthy controls with similar age and sex.**

**Data collection and entry**

Data collection was done using questionnaires and interviews. Demographic and clinical features data included age, sex, body mass index, social class, disease duration, quality of life and medications used and disease activity measured using Clinical Disease Activity Index (CDAI) (Aletaha et al., 2005). Cognitive function was assessed by the Six-item Cognitive Impairment Test (6CIT) - Kingshill Version 2000 (Brooke and Bullock, 1999). The 6CIT uses an inverse score and questions are weighted to produce a total out of 28. Scores of 0-7 were considered normal and eight or more were significant cognitive impairment.

**Statistical analysis**

Continuous data were presented as Mean ± SD while categorical data as numbers and percentages. A chi-square test was used to measure the difference between categorical data. Univariate linear regression analysis then multiple linear regression analysis was used to assess the correlation between cognitive impairment test score with various variables in patients. SPSS v22 and Graph pad Prism v7 software for Windows were used. p-value < 0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

A total of 130 patients and 130 healthy controls participated in the study. The mean age of patients was 48.9 ± 12.1 years and for controls was 48.5 ± 12.1 years (p= 0.794). Females were 100 (76.9%) for patients and 100 (76.9%) for controls (p=1.00). Other sociodemographic and clinical characteristics were shown in Table 1.

Prevalence of memory impairment was more in RA patients (47(69.1%) than controls 21(30.9%) [OR (95%CI)=2.939(1.632-5.294, p<0.001] Figure 1. Age and prednisolone use were significantly and
positively correlated with memory impairment (r = 0.346, p<0.001; r=0.224, p= 0.012 respectively) while the educational level was significantly and negatively correlated with CIT ( r=-0.489, p<0.001) as shown in Table 2.

This study evaluated the impact of RA on memory. It showed that memory impairment was more in RA patients than controls. RA increased the risk of having cognitive impairment with three folds. Also, increasing age and steroid use were significantly and positively correlated with cognitive impairment scores, while the educational level was significantly and negatively correlated with it. These findings are clinically important because early screening for cognition impairment may help early diagnosis and treatment, which will impact positively on health-related quality of life by improving adherence and response to treatment of RA. The inflammation in the brain, high risk of cardiovascular comorbidity, immunosuppressive agents, and Glucocorticoid therapy (Hart et al., 2003; Shin et al., 2012) are possible causes of more memory deterioration in RA. Similar findings were reported by previous studies. (Shin et al., 2012; Appenzeller et al., 2004; Bartolini et al., 2002), who observed more memory drop in RA.

In the current study, we found a significant direct correlation between memory impairment with age, this in line with (Bartolini et al., 2002; Kim et al., 2017) which concluded that aging might contribute to memory drop. Also, low education, and use oral glucocorticoids were associated with memory impairment. These findings were in agreement with (Shin et al., 2012) who demonstrated that persons with less education, and use of oral glucocorticoid were more likely to be cognitively impaired.

Table 1: Baseline characteristic of patients and controls

| Variables                        | Patients (n=130) | Control (n=130) | p-value |
|----------------------------------|-----------------|----------------|---------|
| Age (years), mean ± SD           | 48.9 ± 12.1     | 48.5 ± 12.1    | 0.794   |
| BMI (kg/m2), mean ± SD           | 28.6 ± 4.1      | 28.3 ± 3.6     | 0.484   |
| Gender, n (%)                    |                 |                |         |
| Females                          | 100 (76.9%)     | 100 (76.9%)    | 1.0     |
| Marital status, n (%)            |                 |                |         |
| Single                           | 15 (11.5%)      | 11 (8.5%)      | 0.329   |
| Married                          | 85 (65.4%)      | 83 (63.8%)     |         |
| Widow                            | 28 (21.5%)      | 29 (22.3%)     |         |
| Divorced                         | 2 (1.5%)        | 7 (5.4%)       |         |
| Employment, n (%)                |                 |                |         |
| Unemployed                       | 56 (43.1%)      | 58 (44.6%)     | 0.803   |
| Employed                         | 74 (56.9%)      | 72 (55.4%)     |         |
| Income (thousand ID), mean ± SD  | 7.2 ± 4.7       | 7.0 ± 4.6      | 0.790   |
| Education level, n (%)           |                 |                |         |
| Illiterate                       | 16 (12.3%)      | 16 (12.3%)     | 0.074   |
| Primary                          | 47 (36.2%)      | 47 (36.2%)     |         |
| Secondary                        | 47 (36.2%)      | 32 (24.6%)     |         |
| College                          | 20 (15.4%)      | 35 (26.9%)     |         |
| Disease duration (years), mean ± SD | 8.1 ± 6.7    |                |         |
| CDAI, mean ± SD                  | 19.7 ± 8.8      |                |         |
| Positive RF, n. (%)              | 87 (66.9%)      |                |         |
| Positive ACPA, n. (%)            | 52 (40%)        |                |         |
| ESR, mean ± SD                   | 43.1 ± 22.3     |                |         |
| MTX, n. (%)                      | 85 (65.4%)      |                |         |
| Prednisolone, n. (%)             | 79 (60.8%)      |                |         |
| Biological agents, n. (%)        | 89 (68.5%)      |                |         |

SD: standard deviation. BMI: body mass index (kg/m2): kilogram per square meter. ID: Iraqi dinar. P-value>0.05 is significant. n: number. (%) = percentage. CDAI: clinical disease activity index. RF: rheumatoid factor. ACPA: anticitrullinated peptide antibody. ESR: erythrocyte sedimentation rate. MTX: methotrexate.
Table 2: Correlation between Cognitive Impairment Test score with various variables in patients

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | r       | p-value  | r       | p-value  |
| Age                | 0.509   | <0.001 [S] | 0.346   | <0.001 [S] |
| Gender             | -0.059  | 0.504    | -       | -        |
| BMI                | -0.069  | 0.435    | -       | -        |
| Employment         | 0.317   | <0.001 [S] | 0.053   | 0.556    |
| Education level    | -0.659  | <0.001 [S] | -0.489  | <0.001 [S] |
| Crowding index     | 0.139   | 0.115    | -       | -        |
| Disease duration   | 0.166   | 0.059    | -       | -        |
| CDAI               | 0.088   | 0.322    | -       | -        |
| Family income      | -0.285  | 0.001 [S] | -0.081  | 0.365    |
| RF                 | 0.070   | 0.427    | -       | -        |
| ACPA               | 0.013   | 0.887    | -       | -        |
| ESR                | 0.042   | 0.636    | -       | -        |
| MTX                | 0.135   | 0.125    | -       | -        |
| PND                | 0.222   | 0.011 [S] | 0.224   | 0.012 [S] |
| Biological         | 0.004   | 0.968    | -       | -        |

R² = 0.53, multiple linear regression using dummy variables was used, R, partial correlation; CDAI, clinical disease activity index; RF, rheumatoid factor; ACPA, anticitrullinated peptide antibody; ESR, erythrocyte sedimentation rate; MTX, methotrexate; PND, prednisolone. P > 0.05 was considered significant.

Similar finding was demonstrated by (Wolkowitz et al., 1990), who concluded that corticosteroids are related to memory problems.

In this study, there was no significant association between memory impairment and disease activity in RA patients. This was consisting of that reported by (Shin et al., 2012), who reported that disease severity was not a significant predictor of memory impairment in RA patients. On the other hand, this result was in contrast to (Kim et al., 2017), who found disease activity of RA contribute to memory impairment. These controversial studies findings may be due to different classifications of memory impairment and diverse assessment methods used and reflect the social and habits of a different society.

In conclusion, RA patients had significantly higher memory impairment compared to control. Increasing age, low education, and using of steroids were significant predictors of memory impairment. There is no significant association between memory impairment and disease activity in RA patients. These findings suggest that memory impairment should be evaluated and assessed in RA patient. Extended evaluation of socioeconomic classes across patient’s life is required and a large prospective study is needed to clarify the results.

REFERENCES

Aletaha, D., Neill, V. P., Stamm, T., Uffmann, M., Pfugbeil, S., Machold, K., ., S. J. 2005. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther, 7(4):796–806.

Aletaha, D., Neogi, T., Silman, A. J. 2010. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 69(9):1580–1588.

Appenzeller, S., Bertolo, M. B., Costallat, L. T. 2004. Cognitive impairment in rheumatoid arthri-
tis. Methods and Findings in Experimental and Clinical Pharmacology, 26(5):339–343.

Bartolini, M., Candela, M., Brugni, M., Catena, L., Mari, F., Pomponio, G., Provinciali, L., ., D. G. 2002. Are behaviour and motor performances of rheumatoid arthritis patients influenced by subclinical cognitive impairments? A clinical and neuroimaging study. Clin Exp Rheumatol, 20(4):491–497.

Boyd, T. D., Bennett, S. P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Potter, H. 2010. GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice. Journal of Alzheimer’s Disease, 21(2):507–518.

Brooke, P., Bullock, R. 1999. Validation of a 6 item cognitive impairment test with a view to primary care usage. International Journal of Geriatric Psychiatry, 14(11):936–940.

Coluccia, D., Wolf, O. T., Kollias, S., Rozendaal, B., Forster, A., Quervain, D. J. D., ., F. 2008. Glucocorticoid therapy-induced Memory Deficits: Acute versus Chronic Effects. Journal of Neuroscience, 28(13):3474–3478.

Erickson, A. R., Cannella, A. C., Mikuls, T. R., Firestein, G. S., Budd, R. C., Gabriel, S. G., Mcinnes, I. B., Dell, O. ., ., J. R. 2017. Clinical Features of Rheumatoid Arthritis. 10th edition.

Evren C 2017. Cannabis Use and Cognitive Function. Handbook of Cannabis and Related Pathologies, pages 70–78.

Gorelick, P. B. 2010. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences, 1207(1):155–162.

Hart, R. P., Wade, J. B., Martelli, M. F. 2003. Cognitive impairment in patients with chronic pain: The significance of stress. Current Pain and Headache Reports, 7(2):116–126.

Julian, L. J., Yazdany, J., Trupin, L., Criswell, L. A., Yelin, E., Katz, P. P. 2012. The validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care & Research, 64(3):448–454.

Kim, G. T., Tag, H. S., Kim, Y. K., Lee, S. G., Park, E. K., Park, J. H., Lee, J. W., Kim, S. H., ., J.-H. L. 2017. THU0144 Cognitive function of patients with rheumatoid arthritis is associated with disease activity but not carotid atherosclerotic changes. Annals of the Rheumatic Diseases, 76(2):255–255.

Kurne, A., Karabudak, R., Karadag, Ö., Yalcin-Cakmakli, G., Karli-Oguz, K., Yavuz, K., Topcuoglu, M. A. 2009. An unusual central nervous system involvement in rheumatoid arthritis: a combination of pachymeningitis and cerebral vasculitis. Rheumatology International, 29(11):1349–1353.

Pamuk, O. N., Kiscakic, B., Pamuk, G. E., Onat, A. M., Sayarlioglu, M., Donmez, S., Keystone, E. C. 2013. Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study. Rheumatology International, 33(10):2631–2635.

Shah, A., Kasper, C. E. R. A., Fauzi, D., Hauser, A., Longo, S., Jameson, D., Loscalzo, J. L., ., J. 2017. 4th edition.

Shin, S. Y., Katz, P., Wallhagen, M., ., J. L. 2012. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res, 64(8):1144–1150.

Wallin, K., Solomon, A., Kärehol, I., Tuomilehto, J., Soininen, H., Kivipelto, M. 2012. Midlife Rheumatoid Arthritis Increases the Risk of Cognitive Impairment Two Decades Later: A Population-Based Study. Journal of Alzheimer’s Disease, 31(3):669–676.

Wolkowitz, O. M., Reus, V. I., Weingartner, H., Thompson, K., Breier, A., Doran, A., Pickar, D. 1990. Cognitive effects of corticosteroids. American Journal of Psychiatry, 147(10):1297–1303.